For anemia and thrombocytopenia, the combination therapies of Abemaciclib and Palbociclib pose a higher risk than using aromatase inhibitors or Fulvestrant alone, with no statistical significance in comparison with Ribociclib (Figures 3B, C). This evidence concerns the gene CYP19A1 and anemia (phenotype).